A trial to to study the effect of age on the efficacy and safety of interferon-free treatments with new direct antivirals (NDAV) in patients with hepatitis C
Latest Information Update: 21 May 2019
At a glance
- Drugs Daclatasvir (Primary) ; Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ANGH; APROVVIE
- 12 May 2016 New trial record
- 17 Apr 2016 Results (n=987) presented at The International Liver Congress™ 2016.
- 17 Apr 2016 Results (n=364) presented at The International Liver Congress™ 2016.